Viatris Focuses On Being First In Race For Eylea Biosimilar
‘We Will Be Filing Within This Year’ Indicates Viatris President Malik
Viatris has reiterated the strength of its biosimilars and complex generics pipeline, highlighting opportunities including biosimilar Eylea, Botox and once-a-month Copaxone.
